Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Fabio Guolo

Fabio Guolo

IRCCS Ospedale Policlinico San Martino
Selecting patients with secondary AML for CPX-351 1:14
Selecting patients with secondary AML for CPX-351
Fabio Guolo • 13 Jun 2025
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification 1:15
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
Fabio Guolo • 13 Jun 2025
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML 1:19
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
Fabio Guolo • 6 Dec 2024
Impact of high-risk mutations on outcomes of patients with AML receiving CPX-351 induction 1:23
Impact of high-risk mutations on outcomes of patients with AML receiving CPX-351 induction
Fabio Guolo • 6 Dec 2024
Real-world evidence of the efficacy of CPX-351 in secondary AML 1:01
Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo • 6 Dec 2024
Reducing chemotherapy-induced adverse events in patients with AML 0:43
Reducing chemotherapy-induced adverse events in patients with AML
Fabio Guolo • 16 Jun 2024
The promise of CPX-351 in secondary AML 0:36
The promise of CPX-351 in secondary AML
Fabio Guolo • 15 Jun 2024
A real-world study of the optimal duration of CPX-351 treatment in patients with AML 0:52
A real-world study of the optimal duration of CPX-351 treatment in patients with AML
Fabio Guolo • 15 Jun 2024
Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL 2:55
Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL
Fabio Guolo • 10 Dec 2023
Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML 1:25
Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML
Fabio Guolo • 10 Dec 2023
Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AML 1:30
Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AML
Fabio Guolo • 10 Dec 2023
Novel AML treament approaches 3:10
Novel AML treament approaches
Fabio Guolo • 10 Jun 2020
Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML 2:26
Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML
Fabio Guolo • 11 Jun 2020
CPX-351 in poor risk AML patients 2:16
CPX-351 in poor risk AML patients
Fabio Guolo • 11 Jun 2020
MRD in AML clinical practice 2:05
MRD in AML clinical practice
Fabio Guolo • 14 Jun 2018
MRD: common misconceptions and clinical considerations 1:56
MRD: common misconceptions and clinical considerations
Fabio Guolo • 14 Jun 2018
The content of VJHemOnc is intended for healthcare professionals